SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-055431
Filing Date
2021-10-29
Accepted
2021-10-29 16:10:40
Documents
14
Period of Report
2021-10-25
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea149564-8k_jaspertherap.htm   iXBRL 8-K 48505
2 JASPER THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY ea149564ex10-1_jaspertherap.htm EX-10.1 28464
  Complete submission text file 0001213900-21-055431.txt   305419

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE jspr-20211025.xsd EX-101.SCH 3931
4 XBRL DEFINITION FILE jspr-20211025_def.xml EX-101.DEF 26863
5 XBRL LABEL FILE jspr-20211025_lab.xml EX-101.LAB 37111
6 XBRL PRESENTATION FILE jspr-20211025_pre.xml EX-101.PRE 25481
7 EXTRACTED XBRL INSTANCE DOCUMENT ea149564-8k_jaspertherap_htm.xml XML 5889
Mailing Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065
Business Address 2200 BRIDGE PKWY SUITE #102 REDWOOD CITY CA 94065 6505491400
Jasper Therapeutics, Inc. (Filer) CIK: 0001788028 (see all company filings)

IRS No.: 842984849 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39138 | Film No.: 211363345
SIC: 2836 Biological Products, (No Diagnostic Substances)